Active Biotech

November 10, 2011 10:01 ET

Active Biotech's election committee appointed

LUND, SWEDEN--(Marketwire - Nov 10, 2011) -

In accordance with a decision made by the Annual General Meeting held on May 5, 2011, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September, and the Chairman of the Board.

For the 2012 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:

Johnny Sommarlund, MGA Holding Tomas Billing, Nordstjernan Eggert Mörling, East Bay AB

Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals for the Board of Directors that are to be presented to and decided upon at the Annual General Meeting on May 10, 2012.

Lund, November 10, 2011 Active Biotech AB (publ)

Tomas Leanderson President and CEO

About Active Biotech Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for Systemic Sclerosis as well as RhuDex™ for RA. Please visit for more information.

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on November 10, 2011 at 4:00 p.m.

Active Biotech's election committee appointed:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE


Contact Information

  • Active Biotech AB
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0)46-19 11 00